Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
Noise can play an important role in the initiation and progression of ischemic heart disease. Researchers from the Department of Cardiology at the University Medical Center Mainz have found that noise exposure...
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.
Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.
A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.
Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.
Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis
1.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
2.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
3.
According to the Lancet, having cancer and VTE at the same time increases mortality risk.
4.
Could semaglutide be used to treat addiction in addition to obesity?
5.
Routine breast cancer screening can bring better outcomes for patients
1.
Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection
2.
Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer
3.
Understanding Mantle Cell Lymphoma Prognosis.
4.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
5.
Decoding Hamartomas: Understanding Their Causes and Symptoms
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
2.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge